Oligopeptides for Cancer Immunotherapy
Cytotoxic T lymphocytes (CTL) kill tumour cells upon recognition of oligopeptides derived from tumour-associated antigens (TAA). These are presented by major histocompatibility complex (MHC) class I molecules on the surface of the tumour cells. TAA of certain categories differ with respect to their tumour specificity: mutated antigens and so-called “cancer/germ line” (C/G) antigens are considered strictly or highly tumour specific whereas differentiation antigens are expressed in tumours and the tissues the tumours originate from. The expression of C/G antigens was demonstrated in a variety of cancer types.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50
Contact
Dr. Klaus Kobek
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…